Harnessing tumor acidity: innovative lactic acid-responsive promoter enables precision control of CAR-T cell activity in solid tumors
Journal for ImmunoTherapy of Cancer · 2026-02 · 14 (2) · e013672
DOI: 10.1136/jitc-2025-013672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 10.02.2026. Verfasst von Meiqi Feng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institutes of Biomedical Sciences & Clinical Center of Biotherapy at Zhongshan Hospital, Shanghai Institute of Infectious Disease and Biosecurity, Sh…. Hauptthemen laut MEDLINE: Lactic Acid, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Promoter Regions, Genetic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, “Open Competition to Select the Best Candidates” Key Technology Program for Cell Therapy of NTICB.
Abstract (Originalsprache)
Background
The acidic tumor microenvironment (TME) in solid tumors, driven by abnormal metabolism and lactic acid accumulation, suppresses chimeric antigen receptor-T (CAR-T) cell efficacy while posing safety risks from on-target, off-tumor toxicity (OTOT). This study aims to develop a novel CAR-T technology that leverages lactic acid as a tumor-specific trigger to achieve precise control of CAR activity. The objective is to enable adaptation to the acidic TME while maintaining robust anti-tumor efficacy and mitigating OTOT.
Methods
We engineered a lactic acid-responsive promoter (LARP) using RNA sequencing-identified lactic acid-sensitive genes. This promoter was integrated into HER2-targeting CAR to construct LAR CAR-T cells. CAR expression dynamics under acidic vs neutral conditions were quantified via flow cytometry. Phenotypic profiling (memory markers), in vitro cytotoxicity, and cytokine secretion were assessed. In vivo OTOT was evaluated in our previously constructed humanized HER2 mice, while anti-tumor efficacy and OTOT were further tested in this mouse model bearing tumors.
Results
Our findings demonstrate that the LARP responds to lactic acid, leading to increased CAR expression in acidic conditions. The ex vivo-expanded LAR CAR-T cells exhibited an enhanced memory phenotype and superior tumor-killing capacity in vitro under acidity. In vivo, LAR CAR-T cells achieved tumor eradication comparable to conventional CAR-T cells and exhibited significantly enhanced safety profiles, characterized by the absence of acute hepatotoxicity and minimal off-target organ toxicity.
Conclusions
Our LARP strategy exploits tumor acidity as a precise low/high switch for CAR-T cells. By restricting potent CAR expression to the acidic TME while minimizing activity in normal tissues, LAR CAR-T overcomes key barriers of efficacy and OTOT in solid tumors. This lactic acid-sensing paradigm offers a clinically translatable platform for precise immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institutes of Biomedical Sciences & Clinical Center of Biotherapy at Zhongshan Hospital, Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Public Health Clinical Center, Shanghai Medical College, Fudan…
- State Key Laboratory of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
- The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China.
- Department of Pathology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China.
- Sinobay Biotechnology Co., Ltd, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- “Open Competition to Select the Best Candidates” Key Technology Program for Cell Therapy of NTICB
Zitieren
APA
Feng, M., Zhang, L., Liao, Q., Zhu, L., Zheng, N., Hu, Y., Zhu, C., Mao, Y., Xue, Y., Xia, A., Zhao, C., Ding, X., Zhang, X., & Xu, J. (2026). Harnessing tumor acidity: innovative lactic acid-responsive promoter enables precision control of CAR-T cell activity in solid tumors. Journal for ImmunoTherapy of Cancer, 14(2), e013672. https://doi.org/10.1136/jitc-2025-013672
Vancouver
Feng M, Zhang L, Liao Q, Zhu L, Zheng N, Hu Y, et al. Harnessing tumor acidity: innovative lactic acid-responsive promoter enables precision control of CAR-T cell activity in solid tumors. Journal for ImmunoTherapy of Cancer. 2026;14(2):e013672. doi:10.1136/jitc-2025-013672
BibTeX
@article{Feng2026,
author = {Feng, Meiqi and Zhang, Linxia and Liao, Qibin and Zhu, Lingyan and Zheng, Nairong and Hu, Yangyang and Zhu, Cuisong and Mao, Yunyu and Xue, Ying and Xia, Ai and Zhao, Chen and Ding, Xiangqing and Zhang, Xiaoyan and Xu, Jianqing},
title = {Harnessing tumor acidity: innovative lactic acid-responsive promoter enables precision control of CAR-T cell activity in solid tumors},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {2},
pages = {e013672},
doi = {10.1136/jitc-2025-013672}
}
EUVIMED